中文摘要：

目的观察瑞舒伐他汀治疗对颈动脉粥样硬化患者单个核细胞过氧化物酶体增生物激活受体（PPARs）的影响。方法入选从未使用过他汀类药物、无症状颈动脉粥样硬化患者20例,采用瑞舒伐他汀（5-20 mg/d）治疗3个月,分别在基线及3个月时化验血脂,采用荧光定量RT PCR及Western blot检测单个核细胞PPARs的表达。结果瑞舒伐他汀治疗后,低密度脂蛋白胆固醇、总胆固醇、三酰甘油水平显著降低（P〈0.05）,高密度脂蛋白胆固醇有所升高,但未达到统计学意义（P〉0.05）。瑞舒伐他汀增加单个核细胞PPARα、β的m RNA水平（P〈0.05）,对PPARγm RNA表达没有明显影响（P〉0.05）。瑞舒伐他汀对3种PPARs核蛋白均有上调作用（均P〈0.05）。瑞舒伐他汀治疗前后,3种PPARs核蛋白变化之间均未发现直线相关关系（P〉0.05）。结论上调单个核细胞PPARs可能是瑞舒伐他汀发挥抗动脉粥样硬化作用的机制之一。

英文摘要：

Objective To investigate the effect of rosuvastatin therapy on PPARs expression in mononuclear cells in patients with carotid atherosclerosis. Methods Twenty asymptomatic patients without previous statin treatment were enrolled. Rosuvastatin were given 5 to 20 mg/day for 3 months. At baseline and 3 months, lipid profile was examined. The m RNA and protein expressions of proliferator-activated receptors（PPAR） in the mononuclear cells were measured with RT-PCR and western blotting, respectively.Results After 3-months rosuvastatin treatment, the levels of LDL-C, TC and TG decreased significantly（P〈0.05）. Compared with baseline, the m RNA expressions of PPAR alpha and beta in the mononuclear cells showed significantly increase（P〈0.05）,but not for PPAR gamma. The protein expressions of all PPARs improved（P〈0.05）.There were no correlations between the changes of three PPARs＇ protein expressions before and after rosuvastatin therapy. Conclusion Upregulation of PPARs levels in the mononuclear cells may relate to the anti-atherosclerosis mechanisms of rosuvastatin.